Navigation Links
Celebrex-derived drug targets common childhood bone tumor
Date:6/21/2012

Jiayuh Lin, PhD, and colleagues at Nationwide Children's Hospital have developed a drug to target the most common cancerous bone tumor in children, osteosarcoma, using a version of the FDA-approved drug, Celebrex. The team will soon begin testing the drug using human and canine tumor cell lines thanks to a two-year, $200,000 grant from Alex's Lemonade Stand Foundation for Childhood Cancer.

Osteosarcoma is an aggressive bone tumor that usually develops during the period of rapid growth that occurs in adolescence. A signaling pathway known as the STAT3 pathway is common in osteosarcoma and is crucial to tumor formation and cancer progression. Blocking STAT3 signaling is considered a potential approach for treating osteosarcoma; however, few drugs are available that can inhibit STAT3 and be clinically relevant.

"One of the main barriers to developing a clinical drug to inhibit STAT3 is finding lead compounds that exhibit desirable drug properties," says Dr. Lin, who is a principal investigator in the Center for Childhood Cancer at The Research Institute at Nationwide Children's Hospital.

Dr. Lin and associate professor at The Ohio State University College of Pharmacy, Chenglong Li, PhD, have found that developing STAT3-selective inhibitors can be accelerated by pairing a novel STAT3 drug discovery method with drug repositioning techniques to create inhibitors with desirable drug properties. Using this method, Dr. Lin's team has developed a STAT3-selective inhibitor, 8A, using the FDA-approved drug, celecoxib (brand name: Celebrex, Pfizer, New York ). Celecoxib is typically prescribed to relieve pain, tenderness, swelling and symptoms of inflammatory conditions like osteoarthritis. 8A is more potent and selective than celecoxib against STAT3 signaling in osteosarcoma cells.

The new funding will allow Dr. Lin's team to develop two additional 8A analogs that would further increase STAT3 binding, while retaining the drug properties of celecoxib. The team will then test all three versions in human and canine osteosarcoma cell lines and in a mouse tumor model. Future research will include collaboration with Cheryl London, DVM, PhD, at The Ohio State University College of Veterinary Medicine to initiate clinical trials of a lead 8A analog in dogs with spontaneous osteosarcoma. Osteosarcoma in dogs is very similar to osteosarcoma in humans. Trials will provide valuable data for human trials as well as help determine the feasibility of using lead 8A analog to treat these tumors in canines.

"This is a unique approach in osteosarcoma targeted therapy," says Dr. Lin. "We feel confident that our findings will advance the field of childhood osteosarcoma treatments."


'/>"/>

Contact: Erin Pope
Erin.Pope@NationwideChildrens.org
614-355-0495
Nationwide Children's Hospital
Source:Eurekalert

Related medicine news :

1. Gene sequencing project identifies potential drug targets in common childhood brain tumor
2. Identity Theft Expert Advises on Why Elders are Targets for Scams and Financial Abuse
3. A closer look at PARP-1 reveals potential new drug targets
4. SMART heart eases heart ache, targets cardiac patients emotional well-being
5. Mayo Clinic: Common blood pressure drug linked to severe GI problems
6. PTSD Symptoms Common After Heart Attack: Study
7. New delivery method improves efficacy of 2 common Parkinsons disease medications
8. Absentminded Errors Common in Older Adults: Study
9. Colds May Be Even More Common Than People Think
10. Sexting Common Among Teens: Survey
11. Researchers determine pathway for origin of most common form of brain and spinal cord tumor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 2017   Montrium , an industry leader ... the IQPC Trial Master Files & Inspection Readiness ... EastHORN Clinical Services has selected eTMF Connect ... management. EastHORN, a leading European contract research organization ... transparency to enable greater collaboration with sponsors, improve ...
(Date:9/22/2017)... SAN DIEGO , Sept. 22, 2017 ... ll medical device is now successfully helping those with ... Union. Fibromyalgia diagnosed Amanda in ... getting dressed and washing my hair, experiencing no sleep ... body in painful spasm… I cannot recommend [the AVACEN ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
Breaking Medicine Technology: